The applicant name appears on FDA premarket approval records for an in vitro diagnostic assay used in histological evaluation of tissue. The supplied collection holds two linked PMA records, both under P980018 and both classified under product code MVC, device class 3, with the advisory committee listed as Pathology. Decision counts across the full collection are one APPR and one OK30; the smaller record sample shows the same split of one APPR and one OK30. These counts describe the supplied filings as of the snapshot date and are not measures of total portfolio, sales or safety performance. [1][2]
The original approved device
P980018 was approved on 1998-09-25 under the trade name DAKO HERCEPTEST, with a receipt date of 1998-05-18 and a Federal Register notice date of 1998-10-27. The applicant's approval statement describes a semi-quantitative immunohistochemical assay to determine HER2 overexpression in breast cancer tissues routinely processed for histological evaluation, indicated as an aid in assessing patients for whom Herceptin (trastuzumab) treatment is being considered. The generic name is recorded as SYSTEM, TEST, HER-2/NEU, IHC. [2]
The 2026 supplement
Supplement P980018/S027 was received 2026-07-20 and decided 2026-09-21 with decision code OK30. It is a 30-Day Notice filed under the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the approval statement covers a supplier's change to the manufacturing site for a device component. The trade name on this record is HercepTest™. The FDA database pages for P980018 note that the device has supplements and that the description, function or indication may have changed, so the labeling shown there reflects the version at the time of approval. [1][3]
Product documentation and applicant identity
A HercepTest™ package insert for automated link platforms, code SK001, 14th edition, states in vitro diagnostic use and describes a semi-quantitative immunocytochemical assay for HER2 protein overexpression in breast cancer tissues routinely processed for histological evaluation and in formalin-fixed, paraffin-embedded cancer tissue from patients with metastatic gastric or gastroesophageal junction adenocarcinoma. The same document lists Agilent Technologies Singapore (International) Pte Ltd. at No. 1 Yishun Avenue 7, Singapore, 768923, as manufacturer, with revision dated 2020.11. [9]
The FDA filing records carry the same Singapore address and identify the applicant as Agilent Technologies Singapore (International) Pte , Ltd. That address is a filing address, not a verified headquarters. The public documents do not establish a parent-subsidiary relationship, brand ownership or corporate structure beyond the applicant name printed on the FDA records and the manufacturer name printed in the package insert. [1][2][9]
